About Golodirsen
Strength:
Injection: IV infusion of 100mg/2mL (50mg/mL) in a single-dose vial.
Recommended Dosage:
The drug is administered by a health care professional once a week directly into the bloodstream through intravenous (a vein) or IV infusion. It takes approximately an hour for Golodirsen to be infused into the body. Before beginning the treatment, it is advisable to assess the levels of serum cystatin C, urine protein-to-creatinine ratio, and urine dipstick.
Important:
Discontinuing the treatment should only occur under the guidance of your physician. Importantly, this medication should not be considered a replacement for standard care. Individuals using Golodirsen should continue to receive all recommended treatments, such as physical therapy and occupational therapy. If you have any questions or concerns, please don’t hesitate to discuss them with your healthcare provider.
To ensure your safe and effective use of Golodirsen, it’s crucial to provide a comprehensive medical history, which includes any allergies, infections, or existing medical conditions. Make sure to disclose all medications you are currently taking, including over-the-counter drugs and herbal supplements.
Warnings & Precautions
Common Golodirsen Side Effects:
Use in Specific Population
Storage and Handling
For the medicine procurement, we follow a simple four-step process.
For the importation of medication, we will require the following documents from the patient:
Once all these documents are provided, the Sansfro team will begin the import license application process. This license is a crucial requirement to facilitate the procurement of the necessary medication upon receiving government approval.
No news found.
Sansfro is committed to bridging the healthcare gap. Our purpose is to bring hope and healing to patients suffering from rare diseases by linking them with life-saving treatments through our Named Patient Program. Join us in our quest for a better and healthier world.
Know More...Can kidney toxicity be a concern with Vyondys 53?
Based on animal data, Vyondys 53 may have the potential to cause kidney toxicity. Therefore, it is recommended to monitor kidney function in patients receiving Vyondys 53. It’s important to note that creatinine levels may not always provide an accurate measure of renal function in patients with Duchenne muscular dystrophy (DMD).
How to manage the side effects of Golodirsen?
Promptly report any side effects or concerns to your healthcare provider, who may recommend pre-medications, adjust the infusion rate, and conduct regular monitoring, including kidney function checks, to ensure the safe and effective use of Golodirsen .
Is there a correlation between exon skipping and dystrophin levels in response to Vyondys 53?
Yes, there is a positive correlation between the level of exon skipping and the increase in dystrophin protein expression observed in patients treated with Vyondys 53.
What is the structure of Golodirsen?
Golodirsen is classified as an antisense oligonucleotide, specifically a phosphorodiamidate morpholino oligomer (PMO). It consists of synthetic molecules with morpholino rings linked by uncharged phosphorodiamidate moieties.
What is Golodirsen and how it relates to Vyondys 53?
Golodirsen and Vyondys 53 are the same drug. Vyondys 53 is the brand name and Golodirsen is a generic name. They are both the same drug with the same mechanism of action and the same target population.
What is the price of Vyondys 53 in India?
Vyondys 53 price in India depends on the product requirement. Request more details by contacting our Patient Support Team at (+91) 93157 05373 or help@sansfro.com.
Medical counselor
India, Andorra, Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe, Afghanistan, Albania, Algeria, American Samoa, Angola, Anguilla, Antarctica, etc.